SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (4583)8/4/2010 2:08:36 PM
From: Ian@SI  Respond to of 4676
 
I got the name of the disease wrong.

...

The companies said the initial filing will seek approval
for patients with homozygous familial hypercholesterolemia, in
which patients are unable to properly metabolize LDL due to
dysfunctional LDL receptors, and may also include patients with
severe hypercholesterolemia.

...



To: Ian@SI who wrote (4583)8/4/2010 3:00:39 PM
From: tuck  Read Replies (1) | Respond to of 4676
 
I think you've got the general idea right, despite any scrambling of the disease names . . . looks like a niche drug. I guess I need to listen to some recent presentation to get an idea of news flow on their other stuff. Should be a bunch of P2 results coming in in the next year.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News